East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Adalimumab
Adalimumab
Routinely available
SMC (880/13)
04/12/2024

Indication

For the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such ther...

For the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies. SMC restriction: prescribing by specialists in paediatric gastroenterology.

Therapeutic Area

Gastro-intestinal system

Status Description

Routinely available in line with national guidance

Formulation

-

Comments

Refer to pathway or local board guidelines for preferred formulation

Link to Advice

880/13

Advice Published

08/07/2013

SMC Submission Type

Abbreviated

SMC Status

Restricted